Young women's breast cancers more aggressive and less responsive to treatment

Young women's breast cancers tend to be more aggressive and less responsive to treatment than the cancers that arise in older women, and researchers at the Duke Comprehensive Cancer Center and the Duke Institute for Genome Sciences and Policy may have discovered part of the reason why: young women's breast cancers share unique genomic traits that the cancers in older women do not exhibit.

"Clinicians have long noted that the breast cancers we see in women under the age of 45 tend to respond less well to treatment and have higher recurrence rates than the disease we see in older women, particularly those over the age of 65," said Kimberly Blackwell, M.D., a breast oncologist at Duke and senior investigator on the study. "Now we're really understanding why this is the case, and by understanding this, we may be able to develop better and more targeted therapies to treat these younger women."

The results appear in the July 10 Journal of Clinical Oncology. The study was funded by the National Cancer Institute.

Duke researchers looked at samples of nearly 800 breast tumors from women in five countries on three continents, and divided them into age-specific cohorts. The investigators found more than 350 sets of genes that were active only in the tumors from women under age 45. Conversely, tumors arising in women over age 65 did not share these activated gene sets.

"The breast tumors that arose in younger women shared a common biology, and this discovery was truly remarkable," Blackwell said. "The genes that regulate things like immune function, oxygen supply and mutations that we know are related to breast cancer, such as BRCA1, were preferentially expressed in the tumors taken from younger women, but when we compared younger women's tumors to older women's tumors, we found those same gene sets were not expressed in the 'older' tumors."

Researchers have already developed compounds that target some of the activated gene expression pathways that the Duke team discovered, and many of these compounds have promise for combating young women's tumors, Blackwell said. Identifying these characteristic gene expression profiles will be an important part of finding new therapies, she said.

"Many of the gene sets we saw in 'younger' tumors distinguished these cancers from 'older' tumors but the reverse was not true -- there was nothing we saw in the older women's tumors that set them apart genomically," Blackwell said. "Identifying these distinguishing characteristics may be the first step in developing more effective treatments for these younger patients."


  1. SORIN SORIN France says:

    My son 32 years old is fighting against this cancer and after 3 different Chemio therapies, the cancer (with metastases) continue to expand. So there is not any more protocol treatment. Is there someone to help me about an actual phase 1 program existing?

    Many thanks, Jaen Louis Sorin

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
New anticancer treatment technology targets cancer cell lysosomes and overcomes drug resistance